VK2735
An investigational GIP and GLP-1 receptor dual agonist in oral and subcutaneous forms, currently in Phase 3 trials. It is not approved for any use.
- Half-life
- 4.2 d
- Out of system
- ~3 weeks
- Route
- Subcutaneous
- Level
- Advanced
Long-acting — weekly dosing keeps levels steady. After the last dose, roughly 97% has cleared in ~3 weeks (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What VK2735 is used for
- GIP and GLP-1 dual agonism targets robust appetite control and weight loss
- Developed in both oral and subcutaneous forms
- Reported rapid weight reduction in early and mid-stage trials
How it's typically used
Trial range: doses are titrated per study protocol in ongoing Phase 3 trials, as reported in the literature.
What to watch for
- GI side effects are common, especially during dose escalation
- Long-term safety and durability data are still being collected
- Investigational; in Phase 3 trials and not approved
About GLP-1 & weight loss
- What they are
- Incretin analogues — GLP-1 and dual/triple agonists. They slow stomach emptying and act on appetite centres in the brain, so you eat less without white-knuckling it.
- How they're run
- One subcutaneous shot a week for most, on the same day each week. Doses climb in steps every four weeks; that slow titration is what keeps side effects tolerable.
- What to watch
- Nausea, constipation, and reflux are near-universal in the first month. Muscle is lost alongside fat unless you keep protein high and keep lifting. Tell any surgeon or anaesthetist you are on one.
Full guide
VK2735: A Tracking Guide for a GIP and GLP-1 Dual Agonist
A harm-reduction look at VK2735, an investigational GIP/GLP-1 agonist in oral and injectable Phase 3 programs, not yet approved.
Other glp-1 & weight loss
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.